Video
Dr. Kaplan discusses patient selection for BPH treatments
Author(s):
“This is the beginning of an exploration and an identification,” says Steven A. Kaplan, MD.
Video Player is loading.
In this video, Steven A. Kaplan, MD, discusses his patient selection process for BPH treatments and shares the take-home message of the study, “UroLift PUL compared to Rezum, TURP and GreenLight PVP: US Medicare and commercial claims analysis reveals lowest complications for PUL and highest retreatment for Rezum,” presented at the 2021 American Urological Association annual meeting. Kaplan is a professor of urology at the Icahn School of Medicine and director of the Men’s Wellness Program at Mount Sinai, New York, New York.
Related Videos
Gopa Iyer, MD, highlights findings from FORAGER-1 in metastatic urothelial carcinoma
Michael Schweizer, MD, shares data on mevrometostat plus enzalutamide in mCRPC
Laura Bukavina, MD, highlights study of urinary microbiome profiling
Kate Gessner, MD, on the mechanisms of immunotherapy failure in RCC
Darren Feldman, MD, on clinical outcomes in R/R testicular germ cell tumors
ASCO GU recap: Insights on 5 key trials
Laurence Albiges, MD, on COSMIC-313 trial of triplet vs doublet combination in aRCC
Francesca Jackson-Spence, MRCP, on efficacy of savolitinib/durvalumab in papillary renal cancer
Gopa Iyer, MD, on durable efficacy of EV/pembrolizumab in urothelial carcinoma
David Braun, MD, on phase 2 trial of an individualized neoantigen therapy for RCC
Related Content
